After nod, doubt on eye drop claim

INDIA'S drug regulator has asked for an explanation from the Mumbai-based pharma company, which claimed that its new eye drop could help people reduce dependency on reading glasses for those suffering from presbyopia, an age-related vision condition.

- KAVITA BAJELI-DATT

Official sources said the Drug Controller General of India (DCGI) had asked for a detailed explanation from ENTOD Pharmaceuticals about their claim that their eye drop Pres Vu, which they had described as a significant milestone in managing presbyopia, a common agerelated vision ailment typically affecting those aged over 40.

The company claimed that the eye drop offers an advanced alternative that augments near vision within 15 minutes and received the DCGI nod.

The company had also claimed that the approval follows an earlier recommendation by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).